---
figid: PMC8194085__fonc-11-684961-g003
figtitle: Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine
organisms:
- Mus musculus
- Cricetus cricetus
- Homo sapiens
- Xenopus laevis
- Cullen corylifolium
pmcid: PMC8194085
filename: fonc-11-684961-g003.jpg
figlink: /pmc/articles/PMC8194085/figure/f3/
number: F3
caption: Oncogene reprogram pyrimidine metabolism in cancer Pyrimidine metabolism
  in cell is regulated by multiple oncogenes and suppressors. Upon the activation
  of epidermal growth factor, c-Myc dictates the CAD transcription by binding the
  CAD promoter while HIF-1α exhibits the same pharmacological effect without the participation
  of EGF. RAS-RAF-MEK-MAPK signaling pathway mediates the phosphorylation of CAD at
  T456 while PKA phosphorylates S1406 of CAD. Besides, mTOC1 activation following
  the PI3K/Akt signaling results in the S6K1-regulated phosphorylation of CAD at S1859,
  which is also inhibited by LKB1 and STAT3 pathways. Both modifications of CAD stimulate
  the pyrimidine de novo pathway flux and promote the pyrimidine synthesis. Cancer
  cells with BRAF, KRAS as well as PTEN mutation dependent more on pyrimidine de novo
  pathway and exhibit synthetic lethal vulnerability upon DHODH inhibitor. Most importantly,
  p53 activation is potentially related to the dysfunction of DHODH.
papertitle: Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine.
reftext: Wanyan Wang, et al. Front Oncol. 2021;11:684961.
year: '2021'
doi: 10.3389/fonc.2021.684961
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.
keywords: metabolic reprogram | pyrimidine metabolism | precision medicine | dihydroorotate
  dehydrogenase | pyrimidine inhibitor
automl_pathway: 0.9177071
figid_alias: PMC8194085__F3
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
redirect_from: /figures/PMC8194085__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8194085__fonc-11-684961-g003.html
  '@type': Dataset
  description: Oncogene reprogram pyrimidine metabolism in cancer Pyrimidine metabolism
    in cell is regulated by multiple oncogenes and suppressors. Upon the activation
    of epidermal growth factor, c-Myc dictates the CAD transcription by binding the
    CAD promoter while HIF-1α exhibits the same pharmacological effect without the
    participation of EGF. RAS-RAF-MEK-MAPK signaling pathway mediates the phosphorylation
    of CAD at T456 while PKA phosphorylates S1406 of CAD. Besides, mTOC1 activation
    following the PI3K/Akt signaling results in the S6K1-regulated phosphorylation
    of CAD at S1859, which is also inhibited by LKB1 and STAT3 pathways. Both modifications
    of CAD stimulate the pyrimidine de novo pathway flux and promote the pyrimidine
    synthesis. Cancer cells with BRAF, KRAS as well as PTEN mutation dependent more
    on pyrimidine de novo pathway and exhibit synthetic lethal vulnerability upon
    DHODH inhibitor. Most importantly, p53 activation is potentially related to the
    dysfunction of DHODH.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Hif1a
  - Cad
  - Dffb
  - Acod1
  - Cgct
  - Braf
  - Braf-rs1
  - Kras
  - Pten
  - Zhx2
  - Mdk
  - ras
  - Hras
  - Rem1
  - Egfr
  - Stk11
  - Stat3
  - Egf
  - Dhodh
  - Pik3r1
  - Rps6kb1
  - Pdk1
  - Pdpk1
  - Akt1
  - Trp53
  - Umps
  - HIF1A
  - CAD
  - DFFB
  - ACOD1
  - BRAF
  - KRAS
  - NRAS
  - PTEN
  - ZHX2
  - ARAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - HRAS
  - EGFR
  - STK11
  - STAT3
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - EGF
  - DHODH
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - RPS6KB1
  - PDK1
  - PDPK1
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPTOR
  - TP53
  - TP63
  - TP73
  - UMPS
---
